leisure time -WSS

leisure time

author：hotspot 2025-08-23 08:56:37 - browse：622

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： There's no autism epidemic. It's an autism diagnosis epidemic

WSS

The Biogen Aduhelm mess could happen again

Problems with a popular proposal to regulate AI in health care

Oprah kicked off a national conversation on obesity. Let's have it

States should stop sabotaging methadone treatment reform

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

explore

leisure time

focus

At least 13 dead in Texas as scorching temps continue

A single Democrat is willing to weaken Medicare negotiation power

Tori Bowie and the unacceptable rates of Black maternal death

Johnson & Johnson sued for allegedly overpaying for workers' drugs

At least 13 dead in Texas as scorching temps continue

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Drug repurposing or repositioning? The language matters

AstraZeneca stays mum on Medicare drug pricing negotiations

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Adopting new red light myopia treatments may be short

explore

Vertex Pharmaceuticals may move headquarters in Boston

Surgery pushed Ben Carson to fame

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

FDA's naming rule on biosimilars has undermined competition

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

entertainment

hotspot

entertainment

knowledge